Poster-Epidemiology and Genetics
October 25, 2021
Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry
Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...
Poster-Disease-modifying Therapy
October 25, 2021
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis
INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...
Poster-Disease-modifying Therapy
October 25, 2021
The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis
Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...
Poster-Disease-modifying Therapy
October 25, 2021
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohns Disease
Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...
Poster-Disease-modifying Therapy
October 25, 2021
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies
Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis
Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...